Jack Stewart, Chairman and Chief Scientific Officer of Soricimed, speaks on proof-of-concept study results at annual cancer research workshop.

Jack Stewart, Chairman and Chief Scientific Officer of Soricimed Biopharma Inc., announced proof-of-concept study results at the annual cancer research workshop put on by The Beatrice Hunter Cancer Research Institute and the Terry Fox Foundation, yesterday, May 27th in Moncton New Brunswick. The study demonstrated that treating breast cancer with Soricimed's peptide-chemotherapy drug conjugate was significantly more effective at inhibiting breast cancer cell growth than the chemotherapy drug alone or a mixture of drug plus peptide. Also, Stewart showcased a set of analytical tools Soricimed has developed to detect early stage ovarian cancer in tumour biopsies.

To learn more about these organizations and their dedication to cancer research you can follow the links below.



Sign up to receive updates from Soricimed

Powered by Innovasium